34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details


臨床試験数 : 133 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-003405-26-DK
(EUCTR)
22/02/201824/04/2017Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) - Treating learning disabilities in Neurofibromatosis 1 using lamotrigine Neurofibromatosis type 1
MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
INN or Proposed INN: lamotrigine
Other descriptive name: LAMOTRIGINE
Erasmus MCNULLNot RecruitingFemale: yes
Male: yes
60Phase 2Spain;Belgium;Denmark;Netherlands
2EUCTR2016-005022-10-DE
(EUCTR)
13/02/201809/11/2017Improvement of synaptic plasticity and cognitive function in RAS pathway disordersImprovement of synaptic plasticity and cognitive function in RAS pathway disorders Noonan Syndrom and Neurofibromatosis Type 1
MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify
Product Name: Lovastatin
INN or Proposed INN: Lovastatin
Other descriptive name: LOVASTATIN
Product Name: Lamotrigin beta
INN or Proposed INN: Lamotrigin
Technische Universität München, Fakultät für MedizinNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Germany
3EUCTR2013-003405-26-ES
(EUCTR)
16/10/201731/07/2017Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 20.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000012614;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Belgium;Spain;Netherlands
4EUCTR2013-003405-26-BE
(EUCTR)
30/04/201530/03/2015Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 17.1;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Lamotrigine dispersErasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Belgium;Netherlands
5NCT02256124
(ClinicalTrials.gov)
October 201417/9/2014Effect of Lamotrigine on Cognition in NF1The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL)Neurofibromatosis Type 1Drug: Lamotrigine;Drug: PlaceboErasmus Medical CenterUniversitaire Ziekenhuizen Leuven;ZonMw: The Netherlands Organisation for Health Research and Development;Hospital Sant Joan de DeuTerminated12 Years18 YearsAll41Phase 2/Phase 3Belgium;Netherlands;Spain
6EUCTR2013-003405-26-NL
(EUCTR)
03/09/201420/09/2013Treating learning disabilities in Neurofibromatosis 1 using lamotrigineThe effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL) Neurofibromatosis type 1
MedDRA version: 17.0;Level: LLT;Classification code 10029270;Term: Neurofibromatosis, type 1 (von Recklinghausen's disease);System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Lamotrigine dispers
INN or Proposed INN: Lamotrigine
Other descriptive name: LAMOTRIGINE
INN or Proposed INN: lamotrigine
Other descriptive name: LAMOTRIGINE
Erasmus MCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 2Netherlands